Immunomet Reveals Development Progress of New Drug Candidate IM156 at ASCO
[Asia Economy Reporter Hyungsoo Park] Immunomet, a cancer drug development company, announced on the 22nd that it will present the Phase 1 clinical trial results of its developing drug ‘IM156’ at the 'American Society of Clinical Oncology (ASCO) 2020,' which will be held online starting from the 29th.
IM156 is the first protein complex 1 (PC1) oxidative phosphorylation (OXPHOS) inhibitor-based anticancer drug to have established a recommended Phase 2 dose (RP2D) in cancer patient groups. The Phase 1 clinical trial, led by Professor Sunyoung Ra, head of the Yonsei Cancer Center at Severance Hospital, conducted dose confirmation tests with 800mg and 1200mg in cancer patients. No side effects were observed. Both the maximum tolerated dose and the recommended Phase 2 dose were secured, and the Phase 2 trial will proceed with an 800mg dose.
The Phase 1 trial confirmed that the drug’s residual amount in the body and blood release rate can be controlled according to the administered concentration. Successful results were confirmed from a pharmacodynamics (PD) perspective. From a pharmacokinetics (PK) perspective, which verifies the efficacy of the cancer treatment mechanism, vascular endothelial growth factor (VEGF) and various tumor markers decreased.
A company official stated, "IM156 is a next-generation anticancer drug pipeline that shows efficacy not only against cancer cells with drug resistance that existing immuno-oncology drugs have not overcome but also in treating various solid cancers such as lung and stomach cancer. Based on the clinical results, we will strive to successfully conduct the Phase 2 clinical trial in the first half of next year."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
ASCO, along with the JP Morgan Healthcare Conference, is the largest event in the pharmaceutical and biotechnology industry. It is attended by over 40,000 participants from 76 countries. Domestic and international companies present their pipeline development achievements to global pharmaceutical and biotechnology stakeholders and engage in technology export discussions.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
